Valuation: Black Diamond Therapeutics, Inc.

Market Cap 103M 91.8M 85.91M 77.87M 147M 9.97B 148M 1.03B 401M 5.09B 388M 380M 16.35B P/E 2026 *
-2.92x
P/E 2027 * -1.89x
Enterprise Value 103M 91.8M 85.91M 77.87M 147M 9.97B 148M 1.03B 401M 5.09B 388M 380M 16.35B EV / Sales 2026 *
16.5x
EV / Sales 2027 * -
Free-Float
99.34%
Yield 2026 *
-
Yield 2027 * -
1 day-7.22%
1 week-3.74%
Current month-4.51%
1 month-15.09%
3 months-8.63%
6 months-28.00%
Current year-25.93%
1 week 1.8
Extreme 1.795
1.96
1 month 1.8
Extreme 1.795
2.15
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
8.71
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 2023-09-15
Chief Tech/Sci/R&D Officer 51 2021-08-10
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 49 2018-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 Free

Director

7,707 0.0134%
9/18/26 Free

Director

6,801 0.0118%
9/18/26
NEA Management Co. LLC
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
-7.22%-3.74%-54.08%-31.30% 111M
+4.16%+4.16%+49.37%+94.17% 74.31B
+2.76%-1.60%+22.80%+78.53% 56.95B
+0.24%-1.34%+3.41%+34.31% 48.3B
-3.76%-2.25%+329.09%+698.20% 44.51B
-2.30%-3.35%+26.81%+30.88% 43.8B
+0.31%-0.68%+5.30%+108.64% 41.12B
-0.11%+1.96%+9.19%+52.66% 31.07B
-1.81%+1.43%+35.36%+26.61% 28.97B
-1.96%-2.88%-8.97%-13.92% 24.53B
Average -0.97%-1.08%+41.83%+107.88% 39.37B
Weighted average by Cap. +0.30%-0.94%+56.54%+132.31%

Financials

2026 *2027 *
Net sales 6.25M 5.55M 5.19M 4.71M 8.89M 602M 8.95M 62.36M 24.25M 307M 23.46M 22.96M 988M -
Net income -36.96M -32.81M -30.71M -27.83M -52.56M -3.56B -52.94M -369M -143M -1.82B -139M -136M -5.84B -64.65M -57.39M -53.7M -48.68M -91.93M -6.23B -92.6M -645M -251M -3.18B -243M -237M -10.22B
Net Debt - -
Projected Income Statement - Annual - Black Diamond Therapeutics, Inc.
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
26-10-06 US$1.800 -7.22% 836,039
26-10-05 US$1.940 +2.65% 839,141
26-10-02 US$1.890 +0.53% 472,266
26-10-01 US$1.880 -0.27% 399,124
26-09-30 US$1.885 +0.80% 551,807
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Black Diamond Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.805USD
Average target price
10.00USD
Spread / Average Target
+454.02%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Black Diamond Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. BDTX Stock